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Background: The simultaneous occurrence of metabolic syndrome and excessive daytime sleepiness are very
common in obstructive sleep apnea (OSA) patients. Both conditions, if present in OSA, have been reported to be
associated with inflammation and disruption of oxidative stress balance that impair the cardiovascular system. To
verify the impact of daytime sleepiness on inflammatory and oxidative stress markers, we evaluated OSA patients
without significant metabolic disturbance.
Methods: Thirty-five male subjects without diagnostic criteria for metabolic syndrome (Adult Treatment Panel III)
were distributed into a control group (n = 10) (43 ± 10.56 years, apnea-hypopnea index - AHI 2.71 ± 1.48/hour), a
non-sleepy OSA group (n = 11) (42.36 ± 9.48 years, AHI 29.48 ± 22.83/hour) and a sleepy OSA group (n = 14)
(45.43 ± 10.06 years, AHI 38.20 ± 25.54/hour). Excessive daytime sleepiness was considered when Epworth sleepiness
scale score was ≥ 10. Levels of high-sensitivity C-reactive protein, homocysteine and cysteine, and paraoxonase-1
activity and arylesterase activity of paraoxonase-1 were evaluated.
Results: Patients with OSA and excessive daytime sleepiness presented increased high-sensitivity C-reactive
protein levels even after controlling for confounders. No significant differences were found among the groups in
paraoxonase-1 activity nor arylesterase activity of paraoxonase-1. AHI was independently associated and excessive
daytime sleepiness tended to have an association with high-sensitivity C-reactive protein.
Conclusions: In the absence of metabolic syndrome, increased inflammatory response was associated with AHI and
daytime sleepiness, while OSA was not associated with abnormalities in oxidative stress markers.
Keywords: Obstructive sleep apnea, Excessive daytime sleepiness, Metabolic syndrome, Inflammation, C- reactive
protein, Oxidative stressBackground
A number of observational studies have suggested a strong
association between obstructive sleep apnea (OSA) and
cardiovascular disorders (CVD) [1-3]. Because obesity
seems to be the major risk for both conditions, many stud-
ies have attempted to separate the effects of OSA on risk* Correspondence: vaniadalmeida@uol.com.br
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Metabolic syndrome (MS) is a set of metabolic abnor-
malities that appears to stimulate the development of
atherosclerotic diseases [7], and it may be an important
confounder for cardiovascular consequences of OSA.
OSA associated with MS seems to lead to further car-
diovascular dysfunction involved in the development of
CVD. Greater inflammatory response [8,9], metabolic
impairment [8], worse insulin resistance [10], higher
sympathetic drive [11], increased arterial stiffness [9,12]
and atherosclerosis [12] were detected in patients withl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tent MS is responsible for these consequences.
The pathophysiological mechanisms that may contrib-
ute to the development of CVD in individuals with OSA
arise from sleep fragmentation and intermittent hypoxia
[13], which could lead to the symptom of excessive day-
time sleepiness (EDS). This major symptom of OSA has
been reported to be involved in the association of OSA
and MS [14], even as EDS has also been reported to
predict cardiometabolic complications in OSA patients
[15-19]. Two case–control studies have found associ-
ation between abnormalities on glucose metabolism and
daytime sleepiness [18,19], and another study showed
that only sleepy patients improved insulin resistance and
cholesterol levels after CPAP treatment [19], evidencing
the importance of this symptom on clinic evolution of
OSA patients.
With regard to inflammation, higher levels of inflam-
matory markers were found in sleepy obese patients with
OSA [20]. However, whether EDS is related to inflam-
mation in patients with OSA without obesity or MS has
not been well investigated. In this sense, it is reasonable
to conceive that even in the absence of MS, EDS could
be associated to greater inflammatory response in OSA
patients.
We hypothesized that MS mediates OSA cardiovascu-
lar risk. Therefore, OSA patients without important
metabolic dysfunction would not have major cardiovas-
cular impairment, unless EDS is present. Thus, the aim
of this study was to evaluate biochemical markers of
inflammation and oxidative stress in OSA patients who
do not fit into the diagnostic criteria for MS, as well as
to investigate if EDS can influence these biochemical
parameters.
Methods
Participants
The study included 11 male volunteers (control group)
and 26 male patients with moderate to severe OSA se-
lected from the Cardiovascular Metabolism Center and
the Sleep Clinic at the Universidade Federal de Sao
Paulo (UNIFESP). Moderate to severe OSA was defined
as an apnea-hypopnea index (AHI) > 15/h. The control
group was composed of subjects with AHI < 5/h. We
distributed the OSA subjects into 2 groups according to
excessive daytime sleepiness (non-EDS OSA and EDS
OSA). All participants were asked to arrive at the labora-
tory in the early morning after 12 h of fasting to provide
a blood a sample.
Subjects whose had body mass index (BMI) > 30 kg/m2,
age >60 years, severe chronic pulmonary or cardiac dis-
eases, diabetes mellitus (fasting glucose > 126 mg/dL) [21],
MS according to the modified criteria of the National
Cholesterol Education Program (NCEP) Adult TreatmentPanel III (ATP III) [7] or previous OSA treatment were ex-
cluded. After data collection, 2 participants were excluded:
1 by diabetes mellitus diagnosis (from the control group),
and 1 with MS (from the EDS OSA group).
The study was approved by the Ethics Committee
for Research of the Universidade Federal de Sao Paulo
(CEP1687/08) and was registered with ClinicalTrials.gov
(NCT01635010). All participants gave written informed
consent before being enrolled in the study.
Polysomnography
All participants underwent an overnight polysomnography
including electroencephalography (4 channels: C3-A2, C4-
A1, O1-A2, O2-A1), electrooculogram (2 channels: LOC-
A2, ROC-A1), electromyogram (2 channels: submental and
anterior tibialis muscles), electrocardiogram (1 channel),
and recording of snoring and body position. The airflow
was monitored with a thermistor and a pressure cannula.
Respiratory efforts were detected with ribcage and abdom-
inal piezo sensors. Arterial oxygen saturation and pulse
were monitored by pulse oximetry. Sleep scoring was
conducted according to the criteria of Rechtschaffen
and Kales [22]. Arousals were defined using criteria from
the Sleep Disorders Atlas Task Force of the American Sleep
Disorders Association [23]. Respiratory events, as well as
OSA severity, were defined according to the American
Academy Sleep Medicine Task Force [24]. The AHI was
defined as the number of apneas and hypopneas per hour
of sleep.
Excessive daytime sleepiness
Daytime somnolence was evaluated subjectively using
the Epworth sleepiness scale [25], with a score ≥10 con-
sidered excessive daytime sleepiness.
Definition of metabolic syndrome
MS was diagnosed according to the NCEP ATP III
modified criteria [7] which considers the occurrence of
MS if three of the five following factors were present:
1) waist circumference ≥ 102 cm for men (≥90 cm for
men of Asian origin); 2) triglycerides ≥ 150 mg/dL or
patient on specific drug treatment; 3) HDL < 40 mg/dL
for men or patient on specific drug treatment; 4) arterial
blood pressure ≥ 130 or 85 mmHg respectively for systolic
and diastolic blood pressure, or patient on antihypertensive
drug treatment; 5) fasting glucose ≥ 100 mg/dL or patient
on specific drug treatment.
Blood sampling and biochemical marker determinations
Thirty milliliters of venous blood was obtained from each
participant after a 12 h fasting period. The biochem-
ical variables were high-sensitivity C-reactive protein
(hs-CRP), homocysteine (Hcy) and cysteine (Cys) levels
and paraoxonase-1 (PON-1) activity. As controls for the
Table 1 Characteristics of control, non-EDS OSA and EDS
OSA groups
CONTROL
(n = 10)
non-EDS OSA
(n = 11)
EDS OSA
(n = 14)
Age (years) 43.00 ± 10.56 42.36 ± 9.48 45.43 ± 10.06
BMI (kg/m2) 24.14 ± 2.67 26.65 ± 2.38 27.39 ± 2.05*
Waist Circumference (cm) 89.10 ± 8.78 95.27 ± 8.04 97.93 ± 4.51*
AHI (events/h) 2.71 ± 1.48 29.48 ± 22.83* 38.20 ± 25.54*
Arousal index (events/h) 10.69 ± 5.79 25.91 ± 18.87 32.50 ± 20.53*
MinSatO2 (%) 90.70 ± 2.83 81.91 ± 8.27* 81.50 ± 7.51*
Epworth sleepiness scale 6.90 ± 2.02 6.55 ± 2.11 15.93 ± 4.44*#
Fasting Glucose (mg/dL) 86.80 ± 4.54 93.09 ± 9.58 92.71 ± 11.18
2 h-GTT (mg/dL) 97.00 ± 25.23 121.73 ± 39.01 109.21 ± 25.89
HOMA-IR 0.76 ± 0.31 1.82 ± 1.52 2.02 ± 1.16*
Total Cholesterol (mg/dL) 178.80 ± 40.42 190.73 ± 38.75 191.50 ± 25.63
HDL (mg/dL) 53.60 ± 17.20 52.00 ± 9.58 45.57 ± 7.94
LDL (mg/dL) 109.80 ± 28.89 117.45 ± 33.65 120.43 ± 26.06
VLDL (mg/dL) 15.30 ± 8.15 20.36 ± 8.16 25.50 ± 8.16*
Triglycerides (mg/dL) 77.10 ± 41.13 101.82 ± 41.53 128.07 ± 40.64*
0 component of SM [n, (%)] 5 (50.00) 3 (27.27) 4 (28.57)
1 component of SM [n, (%)] 3 (30.00) 5 (45.45) 5 (35.71)
2 components of SM [n, (%)] 2 (20.00) 3 (27.27) 5 (35.71)
BMI = body mass index; AHI = Apnea-Hypopnea Index; MinSatO2 = Minimum
Oxygen Saturation; 2 h-GTT = 2 h oral glucose tolerance test;
HOMA-IR = homeostasis model assessment index; HDL = High-density
lipoprotein; LDL = Low-density lipoprotein; VLDL = Very-low-density lipoprotein.
Data are presented as the mean ± SD or n (%). ANOVA or Chi-squared. *Different
from control (p < 0.05). #Different from non-EDS OSA group (p < 0.05).
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ate, total cholesterol, LDL, HDL, very low-density lipopro-
tein cholesterol (VLDL), triglycerides, glucose, insulin, and
2 hour oral glucose tolerance test (2 h-GTT).
Serum hs-CRP determination was standardized accord-
ing to the International Federation of Clinical Chemistry
using an International Reference Preparation for Plasma
Proteins (lot CRM 470) certified by the Bureau of Refer-
ence of the European Community. This method has been
referred to as the Reference Preparation for Proteins in
Human Serum lot 91/0619 from the College of American
Pathologists [26]. Image CRPH reagent, which is based on
high-sensitivity immunoassay methodology, was used.
Plasma Hcy and Cys levels were also measured as oxi-
dative stress markers; their determination was based on
the method described by Pfeiffer et al. [27] which uses
high performance liquid chromatography with fluorimetric
detection and isocratic elution. The activity of PON-1 was
assessed by measurement of PON-1 paraoxonase activity
(PON-1sal) and PON-1 arylesterase activity (PON-1are).
These activities were measured by spectrophotometry
using paraoxon and phenylacetate, respectively, as sub-
strates [28]. Vitamin B6 in serum was quantified using
high performance liquid chromatography with ultraviolet
detection and isocratic elution [29]. Serum levels of vita-
min B12 and folate were measured by chemiluminescent
immunoassay with paramagnetic particles using the
Access Immunoassay System (Beckman Coulter Inc., Brea,
California, USA).
Measurement of total cholesterol was performed using
an enzymatic colorimetric method. Calculations of LDL
and VLDL were performed according to the Lipid
Research Clinics Program [30]. Quantitative analysis of
HDL was performed by the immunoinhibition method.
The serum level of triglycerides was measured by the en-
zymatic colorimetric method using glycerol-3-phosphate-
oxidase. The 2 h-GTT was administered in the morning
after at least 10 h of fasting. Blood was collected after fast-
ing and 120 min after oral ingestion of 75 g of glucose.
Plasma glucose was determined using glucose oxidase cal-
orimetric method. Insulin resistance was defined according
to the Homeostasis Model Assessment-Insulin resistance
(HOMA-IR) (fasting glucose [mg/dL] × fasting insulin
[mU/mL]/405) > 2.7 [31]. Serum insulin was determined
by radioimmunoassay.
Statistical analysis
Categorical data were analyzed by Chi-squared test, with
Fisher correction when appropriate, and expressed as
absolute number (%). Due to the sample size, statistical
analyses for all continuous values were performed using
the Z score method for standardization of values, even
though the data were normally distributed. Continuous
variables were expressed as the mean (± standard deviationor standard error). Comparisons of continuous values
among control, non-EDS OSA and EDS OSA groups
were performed using one-way analysis of variance with
Bonferroni post hoc test. An univariate general linear
model for analysis of covariance was used to assess differ-
ences in hs-CRP, Hcy, Cys, PON-1sal, and PON-1are
among the groups, with adjustment for waist circumfer-
ence, HOMA-IR and triglycerides to avoid possible con-
founder effects. In this analysis, the inflammatory and
oxidative stress markers were the dependent variables,
the group category was the fixed factor, and the variables
in the adjustments were covariates. Stepwise multiple lin-
ear regression analysis was performed to evaluate the
influence of AHI, EDS and age on hs-CRP levels. All ana-
lyses were conducted using SPSS software for Windows,
version 13.0 (Chicago, USA). Values of p < 0.05 were con-
sidered statistically significant.
Results
The clinical characteristics of the control, non-EDS OSA
and EDS OSA groups are presented in Table 1. The
groups were similar with respect to age, fasting glu-
cose, 2 h-GTT and total cholesterol, HDL and LDL
levels (Table 1). The Epworth sleepiness scale score was
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control group (p < 0.001) and the non-EDS OSA group
(p < 0.001) (Table 1). AHI was elevated in both non-
EDS OSA and EDS OSA subjects (p < 0.01; p < 0.001,
respectively), MinSatO2 was lower (p < 0.05; p < 0.01, re-
spectively), and arousal index was higher in EDS-OSA
subjects (p < 0.05) than in control subjects, all of these
parameters did not differ significantly between the OSA
groups (Table 1). The EDS OSA group presented elevated
BMI (p < 0.01), waist circumference (p < 0.05), HOMA-IR
(p < 0.05), VLDL (p < 0.05) and triglyceride levels (p < 0.05)
compared to control subjects (Table 1). There was no dif-
ference in the number of MS components presented by
the groups (Table 1).
To avoid possible confounding effects on the studied
markers, analysis of covariance was performed adjusting
for waist circumference, HOMA-IR and triglycerides.
The hs-CRP levels of EDS OSA subjects were higher
than those of the other groups (p < 0.05 for both) even
after adjustments for confounders (Table 2). PON-1sal
and PON-1are activities were similar in the three groups
(Table 2). Plasma Hcy levels were lower in both the non-
EDS OSA (p < 0.05) and the EDS OSA (p < 0.005) groups
than in the control group, and plasma Cys levels were
lower in EDS OSA subjects (p < 0.05) than in controls
(Table 2). There were no significant differences in vita-
min B6, B12 or folate levels among the groups (Table 2).
Stepwise multiple linear regression analysis showed that
AHI was independently associated with hs-CRP (β = 0.314;
p < 0.05); and excessive daytime sleepiness tended to have
an association with hs-CRP (β = 0.245; p = 0.052).
Discussion
In the present study we were able to demonstrate that
middle-aged males with moderate to severe OSA, withoutTable 2 Inflammatory and oxidative stress markers of
control, non-EDS OSA and EDS OSA groups
CONTROL
(n = 10)
non-EDS OSA
(n = 11)
EDS OSA
(n = 14)
Hs-CRP (mg/dL) 0.11 ± 0.08 0.21 ± 0.06 0.41 ± 0.06*#
PON-1 sal (U/mL) 200.47 ± 44.09 202.08 ± 36.15 243.03 ± 35.15
PON-1 are (U/mL) 77.20 ± 9.95 90.96 ± 8.16 81.47 ± 7.93
Hcy (mol/L) 15.09 ± 1.31 10.75 ± 1.07* 9.28 ± 1.04*
Cys (mol/L) 596.59 ± 29.84 526.21 ± 24.47 485.49 ± 23.80*
B6 (nmol/L) 22.91 ± 5.15 25.56 ± 6.12 27.30 ± 8.20
B12 (pg/mL) 368.50 ± 184.12 304.45 ± 87.08 324.64 ± 121.23
Folate (ng/mL) 9.59 ± 4.04 10.95 ± 3.73 10.79 ± 3.51
Hs-CRP = high-sensitivity C-reactive protein; PON-1 sal = PON-1 paraoxonase
activity; PON-1 are = PON-1 arylesterase activity; Hcy = Homocysteine;
Cys = Cysteine. Data are presented as the mean ± SD or SE. Analysis of covariance
adjusted for waist circumference, HOMA-IR and triglycerides. *Different from control
(p < 0.05). #Different from non-EDS OSA group (p < 0.05).significant metabolic dysfunction, had no abnormalities on
studied oxidative stress markers. However, increased in-
flammatory response was found in OSA patients who ex-
hibited daytime sleepiness.
The relationship between OSA, obesity and MS with
inflammation has been explored in the literature. Studies
have demonstrated an association between CRP and
obesity [5,32,33], between CRP and MS [9], or between
other inflammatory markers and visceral obesity [34] in
OSA patients.
However, the impact of isolated OSA on inflammation
is controversial. Punjabi & Beamer [35] and Kokturk
et al. [36] showed significant associations among CRP
levels and OSA in patients without CVD. In a recent
study including non-obese males, hs-CRP, as well as
interleukin-6 levels, were higher in OSA subjects com-
pared to controls [6]. We demonstrated on multiple linear
regression model, that AHI and EDS were independently
associated with hs-CRP. Even after controlling for con-
founding factors, our patients with EDS also presented in-
creased hs-CRP levels.
To the best of our knowledge, the finding that EDS
was independently associated with inflammation in iso-
lated OSA had not yet been well demonstrated. Add-
itionally, we have to emphasize that there is growing
evidence in literature that somnolence in OSA has a
negative influence on cardiometabolic parameters [15-19],
and this symptom predict positive therapeutic response to
CPAP for many outcomes variables [19]. So, even that
other conditions such as metabolic dysfunctions, obesity
or cardiovascular disease that could increase inflammation
are not present in OSA, the occurrence of EDS could be a
marker of inflammation, also reported in our study. In this
sense, our results are in agreement with Vgontzas et al.
data [20], which informed an association of EDS with
inflammatory markers. In opposite, Drager et al. [8],
Bonsignore et al. [10] and Young et al. [37] did not find as-
sociation of EDS with inflammatory markers [8], preva-
lence of MS components, insulin resistance [10], neither
with death rate [37]. We have to take into account that
these studies did not exclude metabolic and cardiovascular
diseases, conditions that could have a major impact on the
research outcomes.
We also should stress out that such differences can
also be partially justified by the subjective measurement
of EDS. Since the multiple sleep latency test - the object-
ive measurement of sleepiness - has not been routinely
included in the workup of these patients. In addition,
sleep deprivation might be a confounder related to som-
nolence, and if sleep deprivation is also independently
associated with inflammation needs to be studied.
Atherogenesis is related to inflammation and to oxida-
tive stress biomarkers. The PON-1 activity has a protect-
ive role [38], while higher Hcy levels are considered an
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studies have addressed PON-1 activity in OSA patients.
Lavie et al. [38] measured PON-1are activity in patients
with OSA plus CVD, patients with OSA without CVD,
and controls. Although stepwise regression analysis dem-
onstrated an independent significant negative association
between AHI and PON-1are activity, PON-1are activity
was lower in the OSA plus CVD group than in controls,
and tended to be lower in the OSA plus CVD group than
in the OSA without CVD group. There were no differ-
ences between OSA without CVD and control groups,
corroborating our findings, in which the exclusion of
CVD and MS resulted in no significant differences in
PON-1 activity among the groups, indicating that OSA it-
self is not associated with alterations on PON-1 activity.
We should take in mind that we can not rule out that
other antioxidants enzymes such as superoxide dismutase
and catalase have participated in prevent the oxidative
stress, however these were not analyzed in our study. Con-
sidering our results we could suggest that OSA patients
were less suitable to disruption of oxidative balance than
those with CVD pointing to the relevance of oxidative
stress in the worsening of apnea syndrome.
Our findings also showed that Hcy and Cys levels were
lower in the OSA group than in the control group. Al-
though the mean values of plasma Hcy were within the
normal range in control and OSA groups (<15 μMol/L
[40]); four subjects (40%) in the control group (two of
them with systemic hypertension), and two subjects (8%)
in the OSA group presented hyperhomocysteinemia. In
fact, even if the literature is controversy regarding the
significance of Hcy levels in OSA, it seems that high
levels of Hcy are observed when OSA is associated with
CVD [41,42]. Excluding the presence of CVD, as in our
study, Ryan et al. [33] and Lavie et al. [42] did not find
elevated Hcy levels related to OSA.
Although statistical treatment was performed to ac-
complish our purpose, one limitation of our study was
the lack of homogeneity of the groups with respect to
BMI, centralization of fat, insulin resistance and lipid
levels. It should be considered that in subjects with OSA
and sleepiness, even without diagnostic criteria for MS,
this observed tendency to develop metabolic dysfunc-
tions and central obesity pattern in combination with in-
creased inflammatory response may be a manifestation
of a future MS. Kono et al. [43] also showed that even in
non obese patients, OSA may predispose to the develop-
ment of MS. Another recent study found similar results
and suggested that OSA is a manifestation of an under-
lying MS [6].
Further aspects of this study should be taken into ac-
count when interpreting our results: i) the exclusion of
women from the sample; ii) the small sample size (this
was due to the difficulty in selecting subjects with OSAand without MS or obesity); iii) the design of the study
(cross-sectional study) does not allow to demonstrate
a causal relationship between OSA and CVD. On the
other hand, most previous studies have investigated the
effects of the association of OSA and MS on the cardio-
vascular system. In the current study, we were able to
separate these two conditions, contributing to better
understand the cardiovascular risk of OSA.
Conclusions
In summary, we have shown that moderate to severe
OSA, in the absence of significant metabolic dysfunc-
tion, did not affect the levels of the studied oxidative
stress markers, while increased inflammatory response
was associated with AHI and daytime sleepiness. These
findings may contribute to understand better the patho-
physiology as well as the importance of recognizing the
somnolent phenotype of OSA.
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